RA Capital Management 13F holdings, Q4 2014
Holdings as of December 31, 2014 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 48 US equity positions worth $776.5m in its Q4 2014 13F filing. The largest position was BCRX at 11.0% of the reported book, followed by ACHILLION PHARMACEUTICALS INC and REGULUS THERAPEUTICS INC. Against the Q3 2014 filing, it opened 12 new positions, added to 4 and reduced 7 among the top 48 holdings.
What did RA Capital Management own in Q4 2014? Top 48 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2014 |
|---|---|---|---|---|---|---|---|
| 1 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 11.0% | $85.7m | 7,050,356 | -0% | held |
| 2 | ACHILLION PHARMACEUTICALS INC | 10.6% | $82.1m | 6,700,000 | 0% | held | |
| 3 | REGULUS THERAPEUTICS INC | 9.8% | $76.1m | 4,742,911 | – | new | |
| 4 | DYAX CORP | 9.0% | $69.5m | 4,945,697 | -37% | reduced | |
| 5 | TGTX TG THERAPEUTICS INC | Healthcare | 6.8% | $53.1m | 3,350,449 | 62% | added |
| 6 | BLUEBIRD BIO INC | 6.0% | $46.4m | 506,122 | -31% | reduced | |
| 7 | DICERNA PHARMACEUTICALS INC | 5.2% | $40.0m | 2,428,571 | 0% | held | |
| 8 | CHRS COHERUS BIOSCIENCES INC | Healthcare | 3.3% | $25.4m | 1,555,355 | – | new |
| 9 | ZS PHARMA INC | 3.0% | $23.5m | 564,483 | 0% | held | |
| 10 | ZAFGEN INC | 2.9% | $22.6m | 732,960 | 0% | held | |
| 11 | XNCR XENCOR INC | Healthcare | 2.9% | $22.4m | 1,399,423 | 12% | added |
| 12 | FORWARD PHARMA A/S | 2.6% | $20.2m | 970,600 | – | new | |
| 13 | NVAX NOVAVAX INC | Healthcare | 2.5% | $19.2m | 3,241,083 | -36% | reduced |
| 14 | SGMOQ SANGAMO BIOSCIENCES INC | Healthcare | 2.4% | $18.6m | 1,220,209 | 0% | held |
| 15 | TREVENA INC | 2.3% | $17.8m | 2,974,647 | – | new | |
| 16 | JUNO THERAPEUTICS INC | 1.9% | $14.6m | 280,000 | – | new | |
| 17 | TXMD THERAPEUTICSMD INC | 1.8% | $14.3m | 3,211,132 | -7% | reduced | |
| 18 | OPHTHOTECH CORP | 1.8% | $13.9m | 310,554 | -47% | reduced | |
| 19 | PROTEON THERAPEUTICS INC | 1.7% | $13.0m | 1,250,000 | – | new | |
| 20 | TENX TENAX THERAPEUTICS INC | 1.3% | $10.3m | 2,670,300 | 14% | added | |
| 21 | BELLICUM PHARMACEUTICALS INC | 1.2% | $9.3m | 1,026,402 | – | new | |
| 22 | AUPH AURINIA PHARMACEUTICALS INC | Healthcare | 1.2% | $9.0m | 2,474,076 | – | new |
| 23 | SCYX SCYNEXIS INC | 1.1% | $8.4m | 840,000 | 0% | held | |
| 24 | ROCKWELL MED INC | 0.9% | $7.3m | 706,252 | – | new | |
| 25 | AKBA AKEBIA THERAPEUTICS INC | Healthcare | 0.9% | $7.0m | 597,363 | 0% | held |
| 26 | VICAL INC | 0.8% | $6.5m | 6,203,690 | 13% | added | |
| 27 | CTI BIOPHARMA CORP | 0.8% | $5.9m | 2,500,000 | – | new | |
| 28 | VERSARTIS INC | 0.7% | $5.2m | 231,267 | -74% | reduced | |
| 29 | AURIS MED HLDG AG | 0.5% | $3.7m | 940,000 | 0% | held | |
| 30 | BIOTA PHARMACEUTIALS INC | 0.4% | $3.1m | 1,378,770 | – | new | |
| 31 | OCERA THERAPEUTICS INC | 0.3% | $2.7m | 417,476 | 0% | held | |
| 32 | T2 BIOSYSTEMS INC | 0.3% | $2.7m | 138,002 | 0% | held | |
| 33 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 0.3% | $2.0m | 17,600 | 0% | held |
| 34 | WAFERGEN BIO-SYSTEMS INC | 0.2% | $1.7m | 560,000 | 0% | held | |
| 35 | PTCT PTC THERAPEUTICS INC | Healthcare | 0.2% | $1.3m | 25,800 | 0% | held |
| 36 | MERRIMACK PHARMACEUTICALS INC | 0.2% | $1.3m | 116,400 | 0% | held | |
| 37 | NEWLINK GENETICS CORP | 0.2% | $1.2m | 30,000 | 0% | held | |
| 38 | ALKS ALKERMES PLC | Healthcare | 0.1% | $1.1m | 19,200 | 0% | held |
| 39 | REGN REGENERON PHARMACEUTICALS | Healthcare | 0.1% | $1.0m | 2,450 | 0% | held |
| 40 | CELG CELGENE CORP | 0.1% | $973.0k | 8,700 | 0% | held | |
| 41 | AMGN AMGEN INC | Healthcare | 0.1% | $940.0k | 5,900 | 0% | held |
| 42 | RGEN REPLIGEN CORP | Healthcare | 0.1% | $891.0k | 45,000 | 0% | held |
| 43 | BIIB BIOGEN IDEC INC | Healthcare | 0.1% | $883.0k | 2,600 | 0% | held |
| 44 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 0.1% | $867.0k | 27,300 | -9% | reduced |
| 45 | KERYX BIOPHARMACEUTICALS INC | 0.1% | $838.0k | 59,200 | 0% | held | |
| 46 | CELLADON CORP | 0.1% | $799.0k | 40,900 | – | new | |
| 47 | KYTHERA BIOPHARMACEUTICALS | 0.1% | $789.0k | 22,750 | 0% | held | |
| 48 | PBYI PUMA BIOTECHNOLOGY INC | Healthcare | 0.1% | $587.0k | 3,100 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.